Institutional members access full text with Ovid®

Share this article on:

Morphologic Diversity of Syringocystadenocarcinoma Papilliferum Based on a Clinicopathologic Study of 6 Cases and Review of the Literature

Kazakov, Dmitry V MD, PhD; Requena, Luis MD; Kutzner, Heinz MD; Fernandez-Figueras, Maria Teresa MD; Kacerovska, Denisa MD, PhD; Mentzel, Thomas MD; Schwabbauer, Peter MD; Michal, Michal MD

American Journal of Dermatopathology: June 2010 - Volume 32 - Issue 4 - pp 340-347
doi: 10.1097/DAD.0b013e3181b96c0c
Original Study

Syringocystadenocarcinoma papilliferum is an extremely rare cutaneous adnexal neoplasm. The purpose of our investigation was to study a series of syringocystadenocarcinoma papilliferum to document morphologic variations of the neoplasm. This is a light-microscopic study of 6 cases of syringocystadenocarcinoma papilliferum obtained from the combined archival, institutional, and consultations files of the authors over 60 years, complemented by a literature review. Syringocystadenocarcinoma papilliferum invariably occurred in association with syringocystadenoma papilliferum and presented as an in situ adenocarcinoma and/or invasive adenocarcinoma. Additionally, an invasive component was represented by squamous cell carcinoma. Variable present features included pagetoid migration of the neoplastic cells, dirty necrosis, mucinous ductal metaplasia, and ductal changes analogous to those seen in the breast. The ductal changes included patterns identical to columnar cell change (flat epithelial atypia), usual ductal hyperplasia, atypical ductal hyperplasia, and ductal carcinoma in situ. A combination of the above patterns in a single lesion was noted. It is concluded that morphologic diversity of syringocystadenocarcinoma papilliferum is substantial. Its association with the benign counterpart and ductal changes suggests a transformation that may involve usual ductal hyperplasia-atypical ductal hyperplasia-(ductal) adenocarcinoma in situ-invasive adenocarcinoma pathway.

From the *Sikl's Department of Pathology, Charles University, Medical Faculty Hospital, Pilsen, Czech Republic; †Department of Dermatology, Fundación Jiménez Díaz, Univesidad Autónoma, Madrid, Spain; ‡Dermatohistopathologische Gemeinschaftspraxis, Friedrichshafen, Germany; §Department of Pathology, Hospital Universitari Germans Trias i Pujol, Autonomous University of Barcelona, Barcelona, Spain; ¶Department of Pathology, Dietrich Bonhoeffer Klinikum Neubrandenburg, Germany; and ‖Bioptical Laboratory, Pilsen, Czech Republic.

Reprints: Dmitry V. Kazakov, MD, Sikl's Department of Pathology, Charles University Medical Faculty Hospital, Alej Svobody 80, 304 60 Pilsen, Czech Republic (e-mail: kazakov@medima.cz).

Copyright © 2010 Wolters Kluwer Health, Inc. All rights reserved.